Macquarie Group’s LYRA THERAPEUTICS INC LYRA Stock Holding History

Macquarie Group’s Portfolio LYRA Stock Details LYRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-28	Closed	-$9	–	2031
2024 Q1	$9	Buy	+28	New	+$7.46K	﹤0.01%	1730

Other funds holding LYRA

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Rosalind Advisors Toronto, Ontario, Canada $249M AUM 80.12% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Macquarie Group's LYRA Position: Q2 2024 in Review

Macquarie Group sold out of LYRA THERAPEUTICS INC (LYRA) in Q2 2024, closing a stake of 28 shares — an estimated $9 sold.

Macquarie Group first reported a position in LYRA in Q1 2024 and held it in 1 quarter. The position peaked at $9 in Q1 2024. 51 funds tracked by Wall St. Rank hold LYRA as of Q2 2024.

Macquarie Group reported no remaining LYRA THERAPEUTICS INC position as of Q2 2024 after selling out during the quarter.
Macquarie Group sold 28 LYRA THERAPEUTICS INC shares in Q2 2024, an estimated $9.
Macquarie Group first reported a position in LYRA THERAPEUTICS INC in Q1 2024 and held it in 1 quarter.
Macquarie Group's LYRA THERAPEUTICS INC position peaked at $9 in Q1 2024.
51 funds tracked by Wall St. Rank held LYRA THERAPEUTICS INC as of Q2 2024.

Based on Macquarie Group's 13F filing for Q2 2024, filed 9 Aug 2024.